Quantinno Capital Management LP Boosts Stock Position in Exelixis, Inc. $EXEL

Quantinno Capital Management LP lifted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 44.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 115,592 shares of the biotechnology company’s stock after purchasing an additional 35,498 shares during the period. Quantinno Capital Management LP’s holdings in Exelixis were worth $4,958,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Exelixis by 48.8% during the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Exelixis by 1.6% during the 4th quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after acquiring an additional 94,218 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Exelixis by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after acquiring an additional 39,920 shares during the period. Morgan Stanley boosted its position in shares of Exelixis by 31.0% during the 4th quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock valued at $184,378,000 after acquiring an additional 995,949 shares during the last quarter. Finally, UBS Group AG boosted its position in shares of Exelixis by 40.2% during the 4th quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock valued at $163,150,000 after acquiring an additional 1,067,265 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of Exelixis stock opened at $52.20 on Friday. The business has a 50-day moving average of $54.10 and a 200 day moving average of $47.90. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $57.57. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of 16.42, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 40.94%. The company had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same period in the prior year, the business earned $0.75 EPS. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts anticipate that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research report on Thursday, July 2nd. Stifel Nicolaus boosted their target price on shares of Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a report on Thursday. Royal Bank Of Canada increased their price target on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Wells Fargo & Company raised their price target on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Finally, Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $49.79.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter adjusted earnings of $0.91 per share, above the roughly $0.85–$0.86 analyst consensus and up from $0.75 a year earlier. Revenue increased 10.6% year over year to $628.7 million, while management highlighted continued execution and progress across its commercial and clinical pipeline. Exelixis Second-Quarter Results
• Positive Sentiment: The company launched a new Phase 3 colorectal cancer study targeting patients with residual disease after surgery. The trial expands the potential market for Exelixis’s pipeline and supports the longer-term growth case for its oncology portfolio. Phase 3 Colorectal Cancer Trial
• Neutral Sentiment: TD Cowen reaffirmed its Buy rating and maintained a $55 price target, citing the resilience of cabozantinib, cost discipline and potential upside from zanzalintinib, while acknowledging the near-term NET guidance reduction. TD Cowen Rating
• Negative Sentiment: Exelixis reduced its 2026 revenue outlook to $2.5 billion–$2.6 billion, below the approximately $2.6 billion consensus, with the midpoint cut by $50 million. The revenue miss and slower-than-expected NET launch raised concerns about near-term growth and prompted reports of lower 2026–2028 earnings expectations. Zacks Earnings and Outlook Report
• Negative Sentiment: Leerink Partners downgraded EXEL from Outperform to Market Perform with a $52 price target, while Zacks Research cut its rating to Strong Sell. Stifel raised its target to $51 but retained a Hold rating, indicating limited perceived upside at current levels.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 43,451 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares in the company, valued at $29,945,209.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sue Gail Eckhardt sold 9,812 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at approximately $806,201.06. The trade was a 37.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 130,824 shares of company stock valued at $6,555,231. Insiders own 2.60% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.